inhaled dual PI3K_,_ kinase inhibitor
Ph. II (3 mg QD) for asthma; withdrawn
from re-opt. of oral PI3K_ inhibitor
Journal of Medicinal Chemistry
AstraZeneca, Gothenburg, SE
AZD8154
1 min read
7. The AstraZeneca inhaled dual PI3K_,_ inhibitor AZD8154 is long-acting in the lung but has low systemic exposure and is selective, potentially avoiding the known side effects of systemic PI3K inhibition. The molecule is active in cells derived from asthmatic patients as well as in a rat model, and entered Ph. 2 trials (NCT04187508) but was withdrawn due to emerging preclinical toxicology findings.
Search By Structure
- H3B-8800
- TPX-0131
- RMC-4529
- ART558
- PF-60873600
- LY3202626
- AZD8154
- vesatolimod
- M-1121
- CHF-6001
- VNRX-7145
- compound 21
- BIO-32546
- leriglitazone
Molecules of the Month
2023
2022
2021
2020